Exhibit 99.1 ADDEX THERAPEUTICS LTD INDEX TO UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS Unaudited Interim Condensed Consolidated Financial Statements Unaudited Interim Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022 2 Unaudited Interim Condensed Consolidated Statements of Comprehensive Loss for the three-month periods ended March 31, 3 2023 and 2022 Unaudited Interim Condensed Consolidated Statements of Changes in Equity for the three-month period ended Ma ...

Addex Therapeutics Ltd. (NASDAQ:ADXN) Q4 2022 Results Conference Call March 30, 2023 10:00 AM ET Company Participants Timothy Dyer - CEO Robert Lutjens - Head, Discovery Biology Conference Call Participants Raghuram Selvaraju - H.C. Wainwright Edouard Riva - ZKB Timothy Dyer Hello, everyone. I'd like to thank you all for attending the 2022 full year financial results conference call. I'm here with Robert Lutjens, our Head of Discovery Biology. I draw your attention to the press release and the financial sta ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to OR ☐ SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF ...

EXHIBIT 99.1 Addex Reports Full Year 2022 Financial Results and Provides Corporate Update CHF 7.0M ($ 7.4M) of cash and cash equivalents at December 31, 2022 ADX71149 Phase 2 study in epilepsy cohort 1 completes part 1 – independent interim review committee (IRC) recommendation expected early Q2 2023 Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, March 30, 2023 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical- stage pharmaceutical company pioneering allosteric modulation-based ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q3 2022 Earnings Conference Call November 11, 2022 11:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Robert Lutjens - Head of Discovery, Biology Mikhail Kalinichev - Head of Translational Science Conference Call Participants Leonildo Delgado - Baader-Helvea Tim Dyer Hello, everyone. I'd like to thank you all for joining our Quarter Three 2022 Financial Results Conference Call. I'm here with Robert Lutjens, our Head of Discovery, Biology; and ...

Addex Therapeutics Ltd (NASDAQ:ADXN) Q2 2022 Earnings Conference Call August 18, 2022 10:00 AM ET Company Participants Tim Dyer - Co-Founder, Board Director and CEO Roger Mills - Chief Medical Officer Robert Lütjens - Head of Discovery, Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Operator Good day and thank you for standing by. Welcome to the Addex Therapeutics to Announce Half Year 2022 Financial Results and provide Corporate Update Conference Call. ...

Addex Therapeutics Limited (NASDAQ:ADXN) Q4 2021 Earnings Conference Call March 10, 2022 10:00 AM ET Company Participants Tim Dyer - CEO Roger Mills - Chief Medical Officer Robert Lutjens - Head of Discovery Biology Conference Call Participants Raghuram Selvaraju - HC Wainwright Bob Pooler - valuationLAB AG Charles Duncan - Cantor Fitzgerald Tim Dyer Hello, everyone. I would like to thank you all for joining our 2020 full year financial results conference call. I am here with Roger Mills, our Chief Medical ...